New PsA Guideline: Anti-TNF is Firstline

New management guidelines for PsA use GRADE methodology

The ACR is about to release its first-ever guideline for the management of psoriatic arthritis (PsA). Written in conjunction with the National Psoriasis Foundation…
From left, Dr. Alexis Ogdie, Dr. Dafna D. Gladman, and Dr. Jasvinder Singh at ACR
TNF inhibitor biologics are recommended as first-line therapy.

While the soon-to-be-revealed ACR-NPA guideline on PsA appears less comprehensive and prescriptive in recommending treatment modalities and targets for the various domains, especially skin (but then, precise information is still scarce for now), it is widely anticipated to favour early and aggressive treatment, to the benefit of patients.

TNF inhibitors are both first and second line for all domains, followed by anti-IL17, anti-IL12/23, before JAK inhibitors.

Biologics more often led to remission in PsA vs conventional drugs

Among patients with psoriatic arthritis, biologics more often led to remission or minimal disease activity…

No Comments Yet.

Leave a comment